Enabling global analysis of protein expression by next generation sequencing

Enabling global analysis of protein expression by next generation sequencing

06-07-2017 12:30 pm - 06-07-2017 1:30 pm
2nd Floor Community Center
953 Indiana Street, San Francisco, CA 94107

RSVP

Amgen Innovator Series

Luciano Brocchieri, PhD
Co-Founder, TB-SEQ

TB-SEQ, Inc., promotes implementations and development of the RIBO-seq platform technology, by which protein expression can be monitored and discovered with high coverage and resolution by deep-sequencing the ‘translatome’, i.e., the genome-wide pool of translated mRNAs. Selective translational control of gene expression is emerging as a widespread mechanism for the regulation of functional activities of biological systems. RIBO-seq has enabled discovery of key regulatory components and mechanisms of post-transcriptional control of translation, uncovering new functionalities and targets for intervention.

About Luciano Brocchieri
Luciano Brocchieri, PhD, Co-Founder of TB-SEQ, was formerly a Senior Scientist at Stanford University, Dept. of Mathematics, and a faculty member at the University of Florida, Department of Molecular Genetics and Microbiology. Luciano has a background in theoretical population genetics, bioinformatics, and molecular evolution. He is the author of extensive work on properties and evolution of protein families and nucleic acid sequences and has developed new methods for gene identification and for the analysis of sequencing data. Luciano is also Editor-in-Chief of the Journal of Phylogenetics and Evolutionary Biology. Along with TB-SEQ Co-founder Silvia Tornaletti, a Stanford-educated biochemist and former faculty member at the University of Florida, have previously collaborated on the analysis of translation in the bacterial pathogen Pseudomonas aeruginosa and in aging muscle.

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter